Molecular Pathogenesis and Targeted Therapies in Well-Differentiated Thyroid Carcinoma
Endocrinology and Metabolism
;
: 211-216, 2014.
Article
in English
| WPRIM
| ID: wpr-80971
ABSTRACT
Four proto-oncogenes commonly associated with well-differentiated thyroid carcinoma, rearranged during transfection (RET)/papillary thyroid cancer, BRAF, RAS, and PAX8/peroxisome proliferator activated receptor-gamma, may carry diagnostic and prognostic significance. These oncogenes can be used to improve the diagnosis and management of well-differentiated thyroid carcinoma. Limited therapeutic options are available for patients with metastatic well-differentiated thyroid cancer, necessitating the development of novel therapies. Vascular endothelial growth factor (VEGF)- and RET-directed therapies such as sorafenib, motesanib, and sunitinib have been shown to be the most effective at inducing clinical responses and stabilizing the disease process. Further clinical trials of these therapeutic agents may soon change the management of thyroid cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Oncogenes
/
Proto-Oncogenes
/
Thyroid Neoplasms
/
Transfection
/
Vascular Endothelial Growth Factor A
/
Diagnosis
Type of study:
Diagnostic study
/
Etiology study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Endocrinology and Metabolism
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS